Back

Tirzepatide versus dulaglutide in type 2 diabetes: a comparative meta-analysis of cardiometabolic outcomes and safety

30 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy in complex settings Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Joe Felipe Maldonado Flores

Tijuana (Mexico)

5 More presentations in this session

Presentation thumbnail
Effects of SGLT2i in the perioperative care of cardiac surgery: a systematic review and meta-analysis of randomised controlled trials
Mr K. Chagas (Itaperuna, BR)
Abstract
Presentation thumbnail
Cardiovascular outcomes by baseline blood pressure control status in persons with type 2 diabetes at high cardiovascular risk treated with oral semaglutide
Professor N. Poulter (London, GB)
Abstract
Presentation thumbnail
Incremental cardiovascular benefit of GLP-1RA added to SGLT2i in type 2 diabetes: a target trial emulation in the US veterans health administration
Doctor J. Lamprea Montealegre (San Francisco, US)
Abstract
Presentation thumbnail
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and extra-valvular cardiac damage undergoing TAVI
Doctor G. Vincelli (Rome, IT)
Abstract
Presentation thumbnail
Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year study
Doctor I. Thymis (Athens, GR)
Abstract

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy in complex settings

The Event

Event poster

ESC Congress 2026

30 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Meta-analysis of cardiovascular outcome trials assessing the cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
27 August 2021
thumbnail
Congress Presentation
Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial
30 August 2025
thumbnail
Congress Presentation
Comparative effectiveness of novel anti-hyperlipidemic drugs in adults with hyperlipidemia: a systematic review and bayesian network meta-analysis
4 April 2025
thumbnail
Congress Presentation
Semaglutide modulates adipogenic differentiation and extracellular acidification in epicardial (EAT) and subcutaneous (SAT) adipose tissue stromal cells from patients with cardiovascular disease.
30 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources